Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bloomberg Customers


February 06, 2016 4:26 PM ET

Pharmaceuticals

Company Overview of Cerecor Inc.

Company Overview

Cerecor, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs for the treatment of patients with neurological and psychiatric disorders. The company has a portfolio of clinical and preclinical compounds, such as CERC-301, CERC-501, and CERC-406. It develops CERC-301 that is in Phase II development stage as an oral, adjunctive antidepressant for the treatment of patients with major depressive disorder (MDD); CERC-501, which is in Phase II development, for co-occurring psychiatric and substance use disorders; and CERC-406 that is its preclinical lead candidate that inhibit catechol-O-methyltransferase within the brain, as well as anticipates developing CERC-406...

400 East Pratt Street

Suite 606

Baltimore, MD 21202

United States

Founded in 2011

12 Employees

Phone:

410-522-8707

Key Executives for Cerecor Inc.

Chief Business Officer
Age: 59
Total Annual Compensation: $407.2K
Scientific Advisor
Age: 58
Total Annual Compensation: $589.1K
Compensation as of Fiscal Year 2014.

Cerecor Inc. Key Developments

Cerecor Inc. Announces Enrollment of First Subject in the Phase 2 Clinical Trial for CERC-501

On February 2, 2016, Cerecor Inc. announced that it had enrolled its first subject in the Phase 2 clinical trial for CERC-501, A Randomized, Double-Blind, Placebo-Controlled, Cross-over Design Study of CERC-501 in a Human Laboratory Model of Smoking Behavior. The study is a thirty-day, double-blind, placebo-controlled, crossover study in subjects who are heavy cigarette smokers and currently not seeking treatment for tobacco use disorder, and the trial design assumes enrollment of 66 subjects. Massachusetts General Hospital CERC-501 Phase 2 Clinical Trial for Treatment-Resistant Depression: The National Institutes of Health (NIH) discontinued the National Institute of Mental Health-funded Phase 2 clinical trial for CERC-501, Double-Blind, Placebo Controlled, Proof-of-Concept Trial of LY2456302, a Kappa Selective Opioid Receptor Antagonist, and Augmentation of Antidepressant Therapy in Treatment-Resistant Depression, which was sponsored by Massachusetts General Hospital. The company has been advised that the reason for the discontinuation is slow study progression.

Cerecor Inc. Appoints Thomas H. Aasen as Director and Member of the Audit Committee

On January 10, 2016, Cerecor Inc. appointed Thomas H. Aasen to the Board. Mr. Aasen will serve as a Class III director and will also serve as a member of the audit committee of the Board. Mr. Aasen served in various roles at Acadia Pharmaceuticals Inc. from 1998 to 2014, most recently as the Executive Vice President, Chief Financial Officer and Chief Business Officer. Previously, Mr. Aasen held financial management positions at three other life sciences companies, including Axys Pharmaceuticals, formerly Sequana Therapeutics, Genta Inc., and Gen-Probe Inc.

Cerecor Inc. Announces Management Changes

Cerecor Inc. announced that Uli Hacksell has been named to the additional positions of CEO and President as of January 1, 2016. Dr. Blake Paterson will step down as the company’s CEO and resign from its board, but will continue to work with the company as a scientific advisor. Dr. Hacksell joined Cerecor Inc. in May 2015 as its Chairman, seeing the company through its initial public offering. Prior to Cerecor, Dr. Hacksell served as Chief Executive Officer of ACADIA from September 2000 to March 2015 and was a member of its Board of Directors.

Similar Private Companies By Industry

Company Name Region
Patheon Puerto Rico, Inc. United States
American Ingredients, Inc. United States
Actelion US Holding Company United States
Power Health, Inc. United States
21st Century Animal Health United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Cerecor Inc., please visit www.cerecor.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.